Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been assigned a consensus recommendation of “Hold” from the seven brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is GBX 1,728 ($22.58).
A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 1,700 ($22.21) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Peel Hunt reiterated a “hold” rating on shares of Hikma Pharmaceuticals in a research note on Monday, September 2nd. Finally, Barclays boosted their price objective on Hikma Pharmaceuticals from GBX 1,800 ($23.52) to GBX 1,900 ($24.83) and gave the company an “equal weight” rating in a research note on Tuesday, August 20th.
Shares of Hikma Pharmaceuticals stock traded down GBX 18 ($0.24) during trading hours on Friday, reaching GBX 2,023 ($26.43). 164,680 shares of the stock traded hands, compared to its average volume of 822,138. The company has a 50 day moving average price of GBX 2,049.47 and a 200 day moving average price of GBX 1,826.52. The firm has a market capitalization of $4.90 billion and a price-to-earnings ratio of 13.60. Hikma Pharmaceuticals has a one year low of GBX 1,491.50 ($19.49) and a one year high of GBX 2,212 ($28.90). The company has a quick ratio of 0.78, a current ratio of 1.28 and a debt-to-equity ratio of 37.69.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Further Reading: Understanding the Price to Earnings Ratio (PE)
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.